State Ledger
Company profile

IN8BIO, INC. CIK 1740279

Ticker
INAB (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
New York, NY 10118
Fiscal year end
2025 (FY)
Market Data
Close
$1.23
Change
-$0.11
Change %
-7.89%
Volume
566

INAB · trading date Oct 12, 2026 · previous close $1.33 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$19.44M
Total assets
$32.28M
Total liabilities
$4.72M
Stockholders' equity
$27.56M
Cash & equivalents
$27.31M
Operating income
-$19.44M
Operating cash flow
-$12.71M
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-03-12. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
14.6%
Equity / assets
85.4%
CapEx / revenue
—
Operating cash flow / net income
0.65×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$19.44M $32.28M $4.72M $27.56M
2024 — -$30.44M $20.94M $6.47M $14.48M
2023 — -$30.01M $33.71M $8.77M $24.94M
2022 — -$28.52M $33.04M $10.31M $22.73M
2021 — -$14.65M $42.22M $4.04M -$38.18M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form SCHEDULE 13G/A
2026-08-13
Financials filed via
Form 10-K
filed 2026-03-12

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
New York, NY 10118
EMPIRE STATE BUILDING
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:45 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New York — Public Companies